Copyright
©2013 Baishideng Publishing Group Co.
World J Gastroenterol. Oct 7, 2013; 19(37): 6278-6283
Published online Oct 7, 2013. doi: 10.3748/wjg.v19.i37.6278
Published online Oct 7, 2013. doi: 10.3748/wjg.v19.i37.6278
Figure 2 Kaplan-Meier analysis of cumulative survival rate in patients with hepatitis B virus-related decompensated cirrhosis treated with lamivudine and adefovir dipivoxil combination therapy and entecavir monotherapy for 96 wk.
LAM: Lamivudine; ADV: Adefovir dipivoxil; ETV: Entecavir.
-
Citation: Lian JS, Zeng LY, Chen JY, Jia HY, Zhang YM, Xiang DR, Yu L, Hu JH, Lu YF, Zheng L, Li LJ, Yang YD.
De novo combined lamivudine and adefovir dipivoxil therapyvs entecavir monotherapy for hepatitis B virus-related decompensated cirrhosis. World J Gastroenterol 2013; 19(37): 6278-6283 - URL: https://www.wjgnet.com/1007-9327/full/v19/i37/6278.htm
- DOI: https://dx.doi.org/10.3748/wjg.v19.i37.6278